Fovista and nesvacumab, drugs that target platelet-derived growth factor and angiopoietin-2, respectively, failed in combination anti-VEGF clinical trials for wet AMD [8,9], probably because of common VEGF-dependent mechanisms of action [10,11,12]. The gene discussed is VEGFA; the disease is wet macular degeneration.